FinDogFinDog
Friday, October 30, 2026Closing data · 4:00 PM ET
English
Log in

VTRS

ViatrisNASDAQ · Pharmaceuticals · Health Care
Previous close
19.04
Change
−0.16 / −0.86%
FinDog View
Neutral
52-Week Range ?
9.92 – 19.51
P/E (TTM) ?
—
Forward P/E ?
6.6
Based on consensus earnings for the next 12 months
Market Cap
$20.7B
1M
+7.42%
S&P 500 −0.91% over same period
Volume / Avg Volume
8.8M / 8.8M
1.00× average
Latest earnings analysisFY2026 Q2Reported 2026-08-06

Viatris Q2 2026: revenue up 5%, adjusted EPS $0.69, guidance raised

Viatris had a solid quarter underneath the headline loss: revenue rose 5% to $3.76 billion, adjusted EPS of $0.69 beat the $0.61 consensus, and management raised every full-year guidance midpoint. The reported GAAP loss of $119 million came from a $177.8 million non-cash charge on the planned Tyrvaya sale, and a $100 million to $150 million supply hit still weighs on the second half. Read the adjusted numbers and the GAAP numbers side by side.

Read the full analysis →
Revenue$3.75BYoY +4.60%
EPS (non-GAAP)$0.69Beatest. $0.61
Next-quarter revenue guidance$14.75B ±1.36%YoY +293.80%
Next-day move+0.86%

Price History

Closing price · USD1M6M1Y5Y
1012.51517.520EFY26 Q2 EarningsEFY26 Q1 EarningsEFY25 Q4 EarningsEFY25 Q3 Earnings2025-102026-012026-052026-082026-10

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →
Report date
2026-11-05
in 4 days · time TBD
Consensus EPS
$0.65
Last quarter EPS $0.69
Avg. next-day move over the last 6 reports
±1.9%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
A 5-year P/E range needs a longer earnings record; not yet comparable
Last 4 quarters: $303M in buybacks + $0 in dividends, 1.47% of market cap combined
P/E (TTM)
—
P/B
1.5
P/S
1.5
Dividend Yield
5.09%
Earnings Reaction
Over the last 6 reports, the stock moved ±1.9% on average on the first trading day after, rising 3 times
Most recent +0.86%
Volatility & Correlation
1-year beta 0.68 · Correlation with S&P 500 0.27Low beta
Annualized volatility 32% vs. 13% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
No open-market buys or sells by officers or directors in the last 90 days.
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q23.75+5.0%38.6%0.01—0.33-0.10
FY2026 Q13.51+8.2%32.8%-0.08—0.350.15
FY2025 Q43.69+5.0%30.8%-0.19—0.62-0.34
FY2025 Q33.75+0.3%36.3%0.18—0.66-0.11
FY2025 Q23.57−5.7%37.0%0.23—0.170.00
FY2025 Q13.24−11.2%35.5%-2.88—0.49-2.55
FY2024 Q43.52−8.1%34.2%-0.18—0.34-0.43
FY2024 Q33.74−5.0%38.7%0.23—0.750.08
FY2024 Q23.79−3.2%37.9%-0.24—0.32-0.27
FY2024 Q13.65−1.8%40.9%0.20—0.560.09
FY2023 Q43.83−1.1%41.4%-0.45—0.40-0.63
FY2023 Q33.93−3.3%42.8%0.45—0.740.27

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView